234. Peroxisomal disease (except Adrenoleukodystrophy) Clinical trials / Disease details
Clinical trials : 39 / Drugs : 35 - (DrugBank : 12) / Drug target genes : 13 - Drug target pathways : 45
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03856866 (ClinicalTrials.gov) | January 11, 2019 | 5/11/2018 | Hydroxychloroquine Administration for Reduction of Pexophagy | Hydroxychloroquine Administration for Reduction of Pexophagy | Zellweger Syndrome;Peroxisome Biogenesis Disorders | Drug: Hydroxychloroquine;Drug: Placebo | The Hospital for Sick Children | NULL | Recruiting | 6 Months | 40 Years | All | 5 | Phase 2 | Canada |